Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5487-92. doi: 10.1016/j.bmcl.2008.09.024. Epub 2008 Sep 10.

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.

Author information

1
AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.

Abstract

An imidazole series of cyclin-dependent kinase (CDK) inhibitors has been developed. Protein inhibitor structure determination has provided an understanding of the emerging structure activity trends for the imidazole series. The introduction of a methyl sulfone at the aniline terminus led to a more orally bioavailable CDK inhibitor that was progressed into clinical development.

PMID:
18815031
DOI:
10.1016/j.bmcl.2008.09.024
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center